NCT05126433 2025-02-28
JAZZ EMERGE201
Jazz Pharmaceuticals
Phase 2 Terminated
Clinical Trials
5 trialsNCT02454972 2023-03-02
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
Phase 2 Completed
NCT02448537 2021-03-03
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Massachusetts General Hospital
Phase 2 Completed
NCT02451007 2019-11-19
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
PharmaMar
Phase 2 Completed
NCT01951157 2019-09-24
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
PharmaMar
Phase 2 Completed